These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 29446288)

  • 21. [Endolymphatic therapy in the treatment of primary delimited melanoblastoma of the skin].
    Korovin SI
    Klin Khir; 1998; (1):39-40. PubMed ID: 9615056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant therapy for malignant melanoma.
    Stoutenburg JP; Schrope B; Kaufman HL
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):823-35. PubMed ID: 15485316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant therapy in melanoma.
    Mohr P; Weichenthal M; Hauschild A
    Onkologie; 2003 Jun; 26(3):227-33. PubMed ID: 12845206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update on the role of adjuvant interferon for high risk melanoma.
    Agarwala SS; Kirkwood JM
    Forum (Genova); 2000; 10(3):230-9. PubMed ID: 11007931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma.
    Trinh VA; Zobniw C; Hwu WJ
    Expert Opin Drug Saf; 2017 Aug; 16(8):933-940. PubMed ID: 28627943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose adjuvant interferon therapy for melanoma.
    Licata AG
    Dermatol Nurs; 1998 Oct; 10(5):334-6. PubMed ID: 9873271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toxicity of combined treatment of adjuvant irradiation and interferon alpha2b in high-risk melanoma patients.
    Conill C; Jorcano S; Domingo-Domènech J; Marruecos J; Vilella R; Malvehy J; Puig S; Sánchez M; Gallego R; Castel T
    Melanoma Res; 2007 Oct; 17(5):304-9. PubMed ID: 17885585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
    Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
    Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant interferon alpha-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-alpha and 5-year follow-up.
    Rusciani L; Proietti I; Paradisi A; Rusciani A; Guerriero G; Mammone A; De Gaetano A; Lippa S
    Melanoma Res; 2007 Jun; 17(3):177-83. PubMed ID: 17505263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of adjuvant interferon in high risk melanoma patients.
    Dermatol Surg; 2000 Jun; 26(6):607-8. PubMed ID: 10848951
    [No Abstract]   [Full Text] [Related]  

  • 31. Rheumatoid arthritis complicating adjuvant interferon-alpha therapy for malignant melanoma.
    Johnson DM; Hayat SQ; Burton GV
    J Rheumatol; 1999 Apr; 26(4):1009-10. PubMed ID: 10229440
    [No Abstract]   [Full Text] [Related]  

  • 32. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
    Bajetta E
    Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604
    [No Abstract]   [Full Text] [Related]  

  • 33. Adjuvant interferon in the treatment of melanoma.
    Middleton MR
    Br J Cancer; 1999 Aug; 80(11):1679-80. PubMed ID: 10468281
    [No Abstract]   [Full Text] [Related]  

  • 34. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696.
    Kirkwood JM; Ibrahim J; Lawson DH; Atkins MB; Agarwala SS; Collins K; Mascari R; Morrissey DM; Chapman PB
    J Clin Oncol; 2001 Mar; 19(5):1430-6. PubMed ID: 11230488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current management of melanoma: benefits of surgical staging and adjuvant therapy.
    McMasters KM; Swetter SM
    J Surg Oncol; 2003 Mar; 82(3):209-16. PubMed ID: 12619066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant interferon alfa-2b for high-risk melanoma.
    Retsas S
    J Clin Oncol; 1996 Jun; 14(6):1968-9. PubMed ID: 8656272
    [No Abstract]   [Full Text] [Related]  

  • 37. Melanoma adjuvant therapy.
    Tarhini AA; Thalanayar PM
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):471-89. PubMed ID: 24880942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum protein s-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon--comparison with tyrosinase rt-PCR.
    Domingo-Domènech J; Molina R; Castel T; Montagut C; Puig S; Conill C; Martí R; Vera M; Auge JM; Malvehy J; Grau JJ; Gascon P; Mellado B
    Oncology; 2005; 68(4-6):341-9. PubMed ID: 16020961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current therapy of cutaneous melanoma.
    Mays SR; Nelson BR
    Cutis; 1999 May; 63(5):293-8. PubMed ID: 10349545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon.
    Mellado B; Del Carmen Vela M; Colomer D; Gutierrez L; Castel T; Quintó L; Fontanillas M; Reguart N; Domingo-Domènech JM; Montagut C; Estapé J; Gascón P
    J Clin Oncol; 2002 Oct; 20(19):4032-9. PubMed ID: 12351601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.